Download in electronic PDF format for $35



Search the Complete Journal Archives

Penfluridol, a Unique Psychiatric Medicine for the Treatment of Chronic Schizophrenia

Author(s):  Zur Eyal

Issue:  Mar/Apr 2019 - Volume 23, Number 2
View All Articles in Issue

Abstract:  Schizophrenia is a serious, disabling, enduring, and relapsing mental illness which causes problems with the ability to think, feel, and perceive things clearly. One cause of relapse and readmission to a hospital is poor compliance with antipsychotic medication, often due to its adverse effects. Schizophrenia may also affect a person’s insight, interfering with their ability to appreciate the benefit of taking medication long term. The relapse rate is significantly higher in those who have discontinued antipsychotic medication. Penfluridol is an unusual, potent, long-acting, first-generation, oral antipsychotic agent indicated for the treatment of chronic schizophrenia, acute psychosis, and Tourette syndrome. It may be considered a depot medication, as it is administered once a week. Despite this positive analysis, and the unique added value of this medication to psychotic, non-compliant patients, Janssen-Cilag, the sole manufacturer of penfluridol worldwide, decided to stop production in 2009. This decision forced many psychotic patients worldwide to abandon the once-a-week convenient treatment and to replace it with a daily, oral treatment or a depot injection. Because penfluridol is no longer commercially available, it has created an opportunity for compounding pharmacists worldwide to accept this challenge and offer this medication to psychiatrists because of its clinical therapeutics. For the past 5 years, penfluridol has been available to compounding pharmacists in Israel and has received favorable feedback from physicians and patients.

Related Keywords: Eyal Zur, BSc Pharm, RPh, MBA, penfluridol, formulations, diphenylbutylpiperidine, chronic schizophrenia, antipsychotic agents, acute psychosis, Tourette syndrome, psychiatric disorders, postsynaptic dopamine receptor, mesolimbic dopaminergic system, neuroleptic adverse effects, drug interactions, herbal supplements, depot administration

Related Categories: FORMULATIONS, MENTAL HEALTH, DOSAGE FORMS/DRUG CARRIERS, NEUROLOGY

Printer-Friendly Version

Related Articles from IJPC
Title (Click for Abstract / Details) Author Issue Page View/Buy
Penfluridol, a Unique Psychiatric Medicine for the Treatment of Chronic Schizophrenia Zur Eyal Mar/Apr 2019 113-119 Buy
Wetting and/or Solubilizing Agents, Featured Excipient: Allen Loyd V Jr Jul/Aug 2001 310 Buy
Burning Mouth Syndrome: A Discussion of a Complex Pathology Zur Eyal May/Jun 2012 196-205 Buy
Using Compounded Medications for the Topical Treatment of Complex Regional Pain Syndrome Type I Following Trauma: A Case Report Zur Eyal Jan/Feb 2014 14-19 Buy
Compounded Analgesic Therapy for Disorders of Movement: Arthritis, Neuropathic Pain, and Postpolio Syndrome Brown Scott, Erickson Brian, Muller George, Bryant-Snure Susan J, Mestayer Richard F III May/Jun 2010 182-192 Buy
Topical Treatment of Primary Focal Hyperhidrosis, Part 2 Zur Eyal Mar/Apr 2019 94-104 Buy
Dopamine Hydrochloride 80-mg/mL Injection Allen Loyd V Jr Nov/Dec 2012 505 Buy
Drug Therapy for Acute and Chronic Pain in the Cat Lascelles B Duncan Sep/Oct 2002 338 Buy
Treatment of Dermatologic Adverse Events Induced by Oncological Treatments Using Compounded Medications Zur Eyal Nov/Dec 2018 446-454 Buy
Topical Treatment of Primary Focal Hyperhidrosis, Part 1 Zur Eyal Jan/Feb 2019 23-31 Buy